Development of a SARS-CoV-2 Delta variant human infection challenge model (COVHIC002)

Research summary

COVHIC002 is a human infection challenge study in which healthy adults aged 18-30 previously vaccinated with an approved COVID-19 vaccine will be administered a SARS-CoV-2 Delta variant virus. The aim is to achieve upper respiratory infection in the majority of challenged individuals with mild or no illness, providing information on the course of SARS-CoV-2 infection and the immune response in vaccinated people. This study will establish an optimised dose and study design that will then be used to evaluate the efficacy of new treatments and vaccine candidates in follow-on trials. Participants will stay in a quarantine unit for around 2 weeks and be followed up by the study team for 1 year. This research is funded by the Wellcome Trust and is being sponsored by Imperial College London. Screening and follow up visits will take place at Imperial College Healthcare NHS Trust and quarantine will take place at the Chelsea and Westminster Hospital.

Principal Investigator

Prof Helen McShane

Contact us

Website: https://trials.ovg.ox.ac.uk/trials/adult

Email: covid19-challenge@paediatrics.ox.ac.uk

IRAS number

318173